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Abstract
Hemolytic uremic syndrome (HUS) is a disease characterized by hemolysis, thrombocytopenia, and
acute kidney injury, although other organs may be involved. Most cases are due to infection with Shiga
toxin-producing Escherichia coli (STEC). Early identification and initiation of best supportive care, with
microbiological input to identify the pathogen, result in a favorable outcome in most patients. The
remaining 10% of HUS cases are classed together as atypical HUS and have a diverse etiology. The
majority are due to inherited or acquired abnormalities that lead to a failure to control complement
activation. Atypical HUS occurring in other situations (for example, related to pregnancy or kidney
transplantation) may also involve excessive complement activation. Plasma therapies can reverse
defective complement control, and it is now possible to specifically target complement activation.
This has led to improved outcomes in patients with atypical forms of HUS. We will review our
current understanding of the pathogenesis of HUS and how this has led to advances in patient care.
Introduction
The thrombotic microangiopathies (TMAs) are a group of
diseases that are characterized by a microangiopathic
hemolytic anemia, thrombocytopenia, and the occlusion
of small vessels by thrombi (Figure 1). Endothelial injury
and an inability to control coagulation are common
features of all of these diseases. The clinical manifestations
of a TMA depend on the site of vascular involvement and,
on the basis of clinical presentation, were classically
divided into two main types: HUS and thrombotic
thrombocytopenic purpura (TTP). HUS typically affects
the microvasculature of the kidney causing acute kidney
injury (AKI), whereas in TTP neurological disease is more
common. However, it is clear that disease classification
based purely on clinical presentation can be misleading, as
HUS can cause neurological disease (as well as affecting
many other organs) and TTP can affect the kidney. In
addition, it is clear that HUS does not represent a single
disease with a common pathogenesis. Instead, HUS is a
group of diseases that are due to different environmental or
genetic factors and that have a similar clinical presentation.
As our understanding of the molecular basis of these
diseases increases, it is now possible to classify HUS and
TTP on the basis of etiology. Most cases of HUS follow
infection with Shiga toxin-producing enteric pathogens
or excessive activation of the complement system. TTP is
due to diminished activity of ADAMTS13 (a disintegrin
and metalloproteinase with a thrombospondin type 1
motif, member 13), an enzyme responsible for the
breakdown of multimeric von Willebrand factor, a pro-
thrombotic protein produced by the endothelium,
megakaryocytes, and vascular connective tissue [1]. It is
evident that a disruption of endothelium function is
common to all TMAs and therefore it is possible that
there are links between the pathways that lead to specific
diseases.
Differentiating between types of TMA on the basis of
clinical parameters is a vital part of patient care.
However, this is not always possible, and diagnostic
accuracy requires identification of the underlying
abnormality. Accurate and early diagnosis is increasingly
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important as new treatments become available that are
specific for different types of TMA and with increasing
evidence that early initiation of treatment improves
patient outcomes. This review will discuss the pathogenic
mechanisms that cause the different types of HUS,
clinical and laboratory diagnosis of HUS, and the
available treatment options.
Pathogenesis of hemolytic uremic syndrome
AlthoughHUS is primarily a disease of the kidney, neurolo-
gical involvement is common, potentially life-threatening,
and an important determinant of mortality [2]. The
incidence of HUS, usually as a consequence of infection,
is higher in children; The overall incidence in the general
population, including adults, is approximately 1 to 2 in
100,000 [3,4]. It can cause dialysis-requiring AKI, severe
multi-organ failure, and death (<5%); however, in most
cases, complete recovery occurs (75%), and the remaining
patients have a reduced glomerular filtration rate, hyper-
tension, or proteinuria [5]. Neurological involvement can
present with irritability, confusion, focal deficit, seizures,
or coma, and involvement of the heart, gastrointestinal
tract, and pancreas has been described.
Most cases of HUS (90%) occur following infection
with STEC, typically serotype O157. Other serotypes of
Escherichia coli can produce toxin, and the largest
recorded outbreak of STEC HUS occurred in Northern
Europe in 2011 because of infection with serotype O104
[6]. Infection is acquired by ingestion of contaminated
food and is followed about 3 days later, although not
invariably [7], by abdominal pain and diarrhea that
progresses to a colitic illness with bloody diarrhea (hence
its previous name: diarrhea-positive HUS). Features of
TMA and AKI develop over the following 3 to 4 days in
5% to 15% of patients with STEC infection [8]. Why only
a small proportion of patients develop HUS following
infection is not known. A genetic predisposition, perhaps
involving genes associated with other forms of TMA, is
possible, and complement gene mutations have been
described in patients with STEC HUS and may predis-
pose them to a poor outcome [9].
Pathogenic STEC strains express adhesins, which are
thought to promote adherence to the intestinal epithelium
following which there is translocation of toxin (usually
Shiga toxin type 2) through the epithelium. It has been
proposed that the toxin could then bind to circulating
leukocytes [10–12], although the evidence for this is
conflicting [13]. The Shiga toxin receptor is a glyco-
sphingolipid: globotriaosylceramide (Gb3). When Shiga
toxin binds Gb3, the complex is internalized and
transported to the endoplasmic reticulum, where the
complex is cleaved to release a protease into the cytoplasm.
This protease inhibits ribosomal function and protein
synthesis, leading to cell death. It can also activate
signaling pathways, inducing an inflammatory response
in affected cells [14]. Although Gb3 is found in other
organs, the kidney is most susceptible to injury. This may
be due to higher levels of Gb3 on renal cells, particularly
the glomerular endothelium (but also podocytes, mesan-
gial, and tubular epithelial cells [15]), the high blood flow
to the kidney, or a greater susceptibility of renal cells to the
effects of the toxin [16]. The expression of Gb3 at other
sites (for example, within the central nervous system)
explains the extra-renal manifestations of STEC HUS.
Figure 1. Glomerular pathology in hemolytic uremic syndrome
(A) In the normal glomerulus, patent capillary lumina containing
erythrocytes stain yellow (arrowhead). (B) In hemolytic uremic syndrome,
the glomerular capillary loops contain fibrin thrombi and microthrombi
that stain bright red (black arrow). There is endothelial cell swelling
with obliteration of some of the capillary lumina (arrowhead) and red
cell fragmentation (red arrow). Stain: Martius scarlet blue trichrome;
magnification: 400×.
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Atypical hemolytic uremic syndrome
Atypical HUS (aHUS) accounts for most of the remaining
10% of cases of HUS. With aHUS, as with STEC HUS, the
kidneys are most frequently involved, but any organ can
be affected. It is difficult to distinguish aHUS from STEC
HUS or TTP on clinical grounds alone. A diagnosis of
aHUS should be considered once STEC infection or
reduced ADAMTS13 activity has been excluded. Although
it is more common in childhood, aHUS can occur at any
age and has a worse prognosis than STEC HUS, with a
3-year patient or kidney survival of 50% [17].
Genetic or acquired defects in control of complement
activation are commonly found in patients with aHUS.
Complement is a complex system of enzymes, effector
proteins, and inhibitors and forms part of the innate
immune system. Low levels of circulating complement
protein C3, suggestive of consumption, were first described
in 1973 [18]. Twenty-five years later, loss-of-function
mutations in the complement regulatory protein comple-
ment factor H (CFH) were described [19]. Since that first
report, loss-of-function mutations in other complement
regulators (complement factor I [20] and membrane
cofactor protein (CD46) [21]) or gain-of-function muta-
tions in complement activators (C3 [22] and complement
factor B [23]), gene rearrangement in CFH and its related
proteins [24], autoantibodies affecting regulator function
[25–27], and “at risk” haplotypes [28,29] have been
described in patients with aHUS. An abnormality in
complement control can be identified in approximately
65% of patients with HUS and is also described in other
glomerular [30–32] and non-renal [33] diseases. aHUS is
usually inherited as an autosomal dominant trait, and
there is incomplete penetrance with approximately 50% of
people with a mutation developing disease [34]. The
incomplete penetrance may be explained by the need for
an environmental trigger, which can include pregnancy
[35], infection (including a diarrheal illness which can
occur in 23% of patients [36]), or drugs [37]. The presence
of more than one mutation or susceptible haplotype may
also increase the risk of disease [36]. Complement
activation, primarily via the alternative pathway, leads to
endothelial damage and activation, leading to small-vessel
thrombosis in target organs (Figure 2).
Not all cases of aHUS are due to defects in proteins
traditionally regarded as important in complement
control. Genetic variants in thrombomodulin, a protein
with anti-fibrinolytic and anti-inflammatory properties,
have been associated with aHUS [38,39]. Thrombomo-
dulin also accelerates the factor I-mediated cleavage of
C3b, and loss of this effect may predispose to aHUS [38].
However, these variants can occur in the general
population and may occur in combination with other
disease-associatedmutations [39,40]. In early childhood,
recessive mutations in diacylglycerol kinase epsilon
(DGKE) cause an HUS-like TMA that frequently pro-
gresses to renal failure [41,42]. How DGKE mutations
cause TMA is not known, but defective DGKE signaling
appears to promote a pro-thrombotic state.
Other forms of hemolytic uremic syndrome
Thrombotic microangiopathic diseases with clinical,
hematological, and histological features of HUS can
occur in response to other triggers. Infection with
neuraminidase-producing Streptococcus pneumoniae
account for 5% of childhood HUS, inducing a severe
TMA with high mortality [43]. One hypothesis for the
link between infection and HUS is that neuraminidase
strips N-acetylneuraminic acid from the glycocalyx of
cells exposing epitopes on endothelial cells, erythro-
cytes, and platelets that are recognized by naturally
occurring antibodies, leading to a pro-thrombotic state.
Treatment is supportive with eradication of Strepto-
coccal infection.
An autosomal recessive defect in vitamin B12 metabo-
lism leads in early childhood to severe TMA, which can
be controlled with daily vitamin B12 treatment [44,45].
The use of quinine is associated with a TMA [46,47] as are
other drugs, in particular calcineurin inhibitors [48,49].
Infections (for example, HIV [50] and malignancy or its
treatment [51]) are also associated with TMA and renal
involvement. In some of these cases, particularly those
related to pregnancy, the association may reflect a
triggering event in patients carrying a genetic defect in
complement control. In a series of patients with
pregnancy-induced HUS, over 80% had a complement
gene mutation [35].
Diagnosis and treatment of patients with STEC
hemolytic uremic syndrome
A diagnosis of STEC HUS should be considered in any
patient developing a TMA, particularly if it follows a
diarrheal illness and is associated with AKI. However,
atypical forms of HUS also may be associated with
diarrhea and therefore STEC infection should be con-
firmed (Figure 3). Stool samples should be sent for STEC
culture, but this may be negative, particularly if sample
collection is delayed [52]. Diarrhea may have stopped by
the time of presentation, but STEC can still be cultured
from feces or rectal swab. Samples should also be assessed
for the presence of Shiga toxin [53]. Shiga toxin can be
detected directly from feces, but the results are variable
[54], and this is best performed after overnight culture.
Polymerase chain reaction-based assays can be used to
detect STEC Shiga toxin genes [55]. Serology can also be
useful indicator of STEC infection [56].
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Best supportive care (BSC), with particular attention to
fluid replacement, renal support, and treatment of
neurological manifestations of the disease, is the main-
stay of treatment for patients with HUS [57,58]. The
improved survival in patients with STEC HUS in recent
years probably reflects better supportive care. Evidence
for the addition of plasma-based therapy to BSC for the
treatment for STEC HUS is limited and it probably has
no role [59,60]. There was a report from the 1990s
suggesting a reduced mortality in older patients treated
Figure 2. Algorithm for the diagnosis of the main types of thrombotic microangiopathy
Abbreviations: ADAMTS13, a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13; HUS, hemolytic uremic syndrome; LDH,
lactate dehydrogenase; PCR, polymerase chain reaction; STEC, Shiga toxin-producing Escherichia coli; TTP, thrombotic thrombocytopenic purpura.
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with plasma exchange [61]. However, several studies
have found no benefit or worse outcomes following
treatment with plasma therapies [59,60], including a
prospective study of 619 children [62] and analysis of
outcomes from the German outbreak [63,64].
The use of antibiotics is controversial. It is recommended
not to use antibiotics to treat STEC infection (E. coliO157)
because of either no benefit or potential increase in the risk
of developing HUS [65–68]. There is evidence that
antibiotic use leads to an increase in toxin production
[69] or release [70]. A study from Japan reported a lower
rate of HUS in patients with STEC infection treated with
fosfomycin [71]. However, this was evident only on
subgroup analysis of the fosfomycin-treated cohort, and
patients in the control cohort may have received other
antibiotics. A beneficial effect of fosfomycin is therefore
unproven. A subsequent meta-analysis failed to show a
harmful or beneficial effect of antibiotics but included the
subgroup analysis from the Japanese study [72,73]. Data
from the 2011German outbreak with E. coliO104 support
the use of antibiotics in patients with established STEC
HUS, with a reduction in seizures, deaths, and require-
ment for abdominal surgery when combined antibiotics
were used [63]. Antibiotics also eliminate STEC from the
gut more rapidly [74] but will have no effect on the
individual patient. It may be that the results from the
German outbreak due to E. coli O104 may not be
generalizable to infections with other serotypes as E. coli
O104, in contrast to O157, does not release increased
quantities of Shiga toxin in response to therapeutic
concentrations of antibiotics [75].
There is evidence from a pre-clinical rodent model of
Shiga toxin-mediated injury that complement activation
may augment the effects of the toxin on cells [76,77],
although no evidence of complement activation was
seen in a primate model [78]. There is also evidence of
complement activation in the circulation of patients with
STEC HUS [79], and a report of three children with
severe neurological involvement suggested a response
to treatment with the anti-C5 monoclonal antibody,
eculizumab [80]. Eculizumab was used extensively
during the German outbreak with no reported benefit
Figure 3. Complement activation in atypical hemolytic uremic syndrome
The complement system, through the alternative pathway, is in a state of continuous low-level activationwith generation of a fluid phase C3 convertase (C3H2OBb).
This generates the fragment of C3, C3b, which can bind to cell membranes, which leads to cell-bound C3 convertase. If unchecked, this process leads to
rapid amplification of complement activation and generation of the effector proteins of the system: C5b-9, C3a, C5a, and more C3b. To prevent this, there are cell
surface (or membrane co-factor protein [MCP]) and fluid phase—complement factor H and complement factor I (CFI)—inhibitors of complement activation.
Failure to adequately control activation leads to endothelial injury, with thrombus formation, red cell fragmentation, and platelet consumption.
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in an analysis of 67 patients [63]. The rate of resolution
of disease was equivalent in eculizumab-treated and
untreated case controls. A report in 2014 of nine cases of
STEC O104 HUS in France suggested a benefit with
eculizumab. However, in that report, unlike the report
from Germany, there were no control cases [81]. The use
of eculizumab in STEC HUS requires further evaluation
before its use can be recommended.
Several other treatments for STEC HUS, including oral
administration of Shiga toxin-binding agents [82], corti-
costeroids, anti-platelet agents, and heparin, have been
suggested but have not proven beneficial [58]. Although
other treatments have been associated with good out-
comes, it is difficult to assess their benefit in a disease that
in most cases is self-limiting. These treatments include
immunoadsorption to treat an immunoglobulin-
mediated component of the neurological disease [83]
and recombinant thrombomodulin [84,85].
Diagnosis and treatment of patients with
atypical hemolytic uremic syndrome
aHUS should be considered in any patient presenting
with a TMA, particularly if the preceding history does not
suggest STEC infection. Clinical features may suggest a
diagnosis of aHUS but alone are insufficient to
confidently diagnose aHUS. Evidence of STEC infection
should be sought, and reduced ADAMTS13 activity
should be excluded [86]. Serum levels of C3, C4, factor
H, and factor I should be measured before plasma
exchange is started. Low C3 concentrations suggest but
are not diagnostic of aHUS [87]. Genetic screening and
testing for autoantibodies should be performed on all
suspected cases. Though important to elucidate the
cause of aHUS, these tests take time and do not form
part of the initial diagnostic algorithm.
Plasma exchange (PE) until recently has been considered
the most effective treatment [88,89]. PE replaces function-
ally defective proteins and removes overactive proteins. It
is also the treatment for TTP and therefore is appropriate
while laboratory investigations are being performed to
differentiate between aHUS and TTP. PE should be started
as soon as the diagnosis is suspected, replacing 1 to
2 plasma volumes in adults and 50 to 100 mL/kg in
children with each treatment. The volume exchanged and
the frequency of treatments should be increased until the
TMA is controlled. In those patients who respond, PE can
be gradually withdrawn, although a significant proportion
will require continued PE to maintain remission.
The effective use of eculizumab in aHUS was first
described in 2009 [90], and since then there have been
many reports of its use [91–94]. Two trials of eculizumab
in adolescents and adults with plasma therapy-resistant
or -dependent aHUS have recently been reported. In total,
37 patients were treated in these open-label, uncontrolled
trials. Eculizumab was effective in more than 80% of
patients, controlling hemolysis, improving renal function,
and allowing the withdrawal of plasma therapy [95].
Treatment of aHUS should be started early (as soon as
other causes of TMA have been excluded on the basis of
clinical and laboratory assessment) since early treatment is
associated with a better renal outcome [96]. There are still
unanswered questions about eculizumab treatment of
aHUS, in particular how long to continue treatment.
Withdrawal of eculizumab is associatedwith relapse, but it
can be withdrawn in some patients, with a recent report
describing successful withdrawal in 7 out of 10 patients
[97]. Because of the risk ofNeisseria meningitides infection,
all patients receiving eculizumab should be vaccinated
and long-term antibiotics should be considered [98].
The rationale for anti-complement treatment in patients
without a defined defect in complement control or with a
non-complement mutation is less clear. Nevertheless,
patients without an identified mutation responded
similarly to treatment with eculizumab [95], which may
reflect a role for complement in the development of aHUS,
even if the causative mutation lies outside the comple-
ment system. There are also links between thrombo-
modulin and complement activation. The exception is
patients with DGKE mutations who appear resistant to
treatment targeting complement activation [41].
Transplantation in patients with hemolytic
uremic syndrome
Although STEC frequently causes AKI, recovery of renal
function usually occurs. Recovery of function may not be
complete, and in some cases maintenance dialysis is
required. In these cases, transplantation is possible
provided that there is no coexisting defect in complement
control [9]. In contrast, aHUS frequently recurs after
transplantation. Overall, 60% of patients develop recur-
rent disease after transplantation, 90% of whom will lose
their graft [99]. The risk of recurrence depends on the
underlying abnormality, with high risk in patients with
factor H, C3, and B mutations but lower risk with CD46
mutations or if no abnormality is detected [99–101].
Recurrent disease after transplantation can be treated
successfully with eculizumab, and 40% of patients in the
recent trails developed disease in a transplanted kidney
[95,102]. Eculizumab can also be used prophylactically to
prevent recurrence in patients at high risk of recurrence
who are undergoing transplantation [96].
As most complement proteins are synthesized in the liver
(with the exception of CD46), combined liver and kidney
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transplantation reverses the complement abnormality,
controls disease, and allows successful kidney transplan-
tation [103,104]. Initial outcomes of combined trans-
plantation were poor [105]. Aggressive plasma exchange
or eculizumab to correct the complement abnormality
prior to transplantation allows successful transplantation
and this option should be discussed with patients [106].
If the predisposing mutation occurs in other pathways,
aHUS can recur after transplantation. Recurrence after
transplantation has been reported in patients with
thrombomodulin mutations [38,107]. Transplantation
has been performed in patients with aHUS due to DGKE
mutations without evidence of recurrent aHUS [41].
The etiology of de novo HUS after transplantation is
complex, and ischemia reperfusion, drugs, and humoral
immunity are potential precipitants. Complementmay also
be involved. Thirty percent of patients who develop de novo
HUS have a complement mutation [108], and even in the
absence of amutation eculizumab can be effective [109].
Conclusions
Most commonly, HUS is due to STEC infection. This
can be a severe, life-threatening disease but in most
cases is self-limiting and will resolve completely.
Treatment is with BSC, and although other treatments,
including plasma therapy, eculizumab, and toxin
binders, have been proposed, there is very little
evidence to support their use outside of clinical trials.
aHUS is, in most cases, due to impaired control of
complement activation. It can be treated effectively with
complement inhibition, but this may not be successful
if treatment is started late or the disease is caused by a
problem in another pathway.
Undoubtedly, progress has been made in the treatment of
HUS. However, there are very few high-quality clinical
trials to guide treatment. HUS is a rare, etiologically
heterogeneous disease and there is a need for multi-
center collaborative studies to test the efficacy of new
treatments and inform best practice in the treatment of
this disease.
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